Gynecologic Disease
Conditions
Brief summary
Postoperative nausea and vomiting (PONV) is commonly accompanied in patients undergoing surgery under general anesthesia. The patients undergoing laparoscopic gynecologic surgery have multiple risk factors for developing PONV such as female gender, nonsmoker, postoperative opioids, and laparoscopic surgery. Thus, it is important to prevent PONV in these patients.
Detailed description
Magnesium is a N-methyl-D-aspartate (NMDA) antagonist that is known to be effective in reducing opioid consumption and controlling postoperative pain. This opioid reducing effect can be associated with reduction of the incidence of PONV. However, the effect of magnesium on preventing PONV have not been investigated before. Thus, the investigators hypothesized that intraoperative infusion of magnesium will be effective in preventing PONV in patients undergoing laparoscopic gynecologic surgery.
Interventions
20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
DRUGControl (saline)
The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
Sponsors
Gangnam Severance Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Gynecologic disease * Female patients undergoing laparoscopic gynecologic surgery and receiving postoperative fentanyl based intravenous patient controlled analgesia (PCA), aged 20-65 years.
Exclusion criteria
* impaired renal or hepatic function (Glutamic Oxalacetate Transaminase \[GOT\]/Glutamic Pyruvate Transaminase \[GPT\]\>50, estimated glomerular filtration rate \[eGFR\]\<60) * atrioventricular block, myopathies, diabetes, treated with calcium channel blockers * History of receiving antiemetics within 1 day before surgery * History of receiving opioids or non-steroidal anti-inflammatory drugs within 1 week of surgery * drugs or alcohol abuse * patients treated with isoniazid, chlorpromazine, or digoxin * patients who cannot communicated with others or with cognitive dysfunction * patients who cannot read informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of PONV | up to postoperative 2 days | The incidence of PONV will be measured up to postoperative 2 days. |
Outcome results
None listed